{
    "organizations": [],
    "uuid": "4b84e57c46bacfe7f68e7226f135084daec324cb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-palatin-technologies-initiates-sub/brief-palatin-technologies-initiates-subject-dosing-in-first-in-human-clinical-study-of-pl-8177-idUSFWN1PV0VL",
    "ord_in_thread": 0,
    "title": "BRIEF-Palatin Technologies Initiates Subject Dosing In First-In-Human Clinical Study Of Pl-8177",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 42 PM / in 8 minutes BRIEF-Palatin Technologies Initiates Subject Dosing In First-In-Human Clinical Study Of Pl-8177 Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Palatin Technologies Inc: \n* PALATIN TECHNOLOGIES, INC. INITIATES SUBJECT DOSING IN FIRST-IN-HUMAN CLINICAL STUDY OF PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST \n* PALATIN TECHNOLOGIES INC - TOP LINE DATA FROM STUDY OF PL-8177 IS CURRENTLY EXPECTED IN Q3 OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-05T14:39:00.000+02:00",
    "crawled": "2018-02-05T14:57:54.072+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "technology",
        "initiate",
        "subject",
        "dosing",
        "clinical",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "palatin",
        "technology",
        "inc",
        "palatin",
        "technology",
        "initiate",
        "subject",
        "dosing",
        "clinical",
        "study",
        "investigational",
        "melanocortin",
        "receptor",
        "agonist",
        "palatin",
        "technology",
        "inc",
        "top",
        "line",
        "data",
        "study",
        "currently",
        "expected",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}